Soligenix
SNGX
$0.42
Share price
-2.81%
Change (1 day)
-73.05%
Change (1 year)
Categories
P/S ratio for Soligenix (SNGX)
P/S ratio as of April 2024 (TTM): 7.04
According to Soligenix's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.0415. At the end of 2023 the company had a P/S ratio of 9.36.
P/S ratio history for Soligenix from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 9.36 | -54.53% |
| 2022 | 20.6 | -40.05% |
| 2021 | 34.3 | 112.11% |
| 2020 | 16.2 | 137.68% |
| 2019 | 6.81 | 134.81% |
| 2018 | 2.90 | -18.66% |
| 2017 | 3.57 | 204.72% |
| 2016 | 1.17 | -70.95% |
| 2015 | 4.03 | 21.05% |
| 2014 | 3.33 | -69.62% |
| 2013 | 11.0 | 414.17% |
| 2012 | 2.13 | 166.77% |
| 2011 | 0.7988 | -96.21% |
| 2010 | 21.1 | 27.96% |
| 2009 | 16.5 | 523.38% |
| 2008 | 2.64 | -79.35% |
| 2007 | 12.8 | 79.41% |
| 2006 | 7.14 | 55.4% |
| 2005 | 4.59 | -82.98% |
| 2004 | 27.0 | |
| 2001 | > 1000 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.79 | -46.24% | 🇺🇸 USA |
 Pfizer PFE | 2.46 | -65.08% | 🇺🇸 USA |
 Sanofi SNY | 2.44 | -65.41% | 🇫🇷 France |
 Onconova Therapeutics ONTX | 92.5 | 1,213.62% | 🇺🇸 USA |
 Athersys ATHX | 10.4 | 47.91% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | 0.9871 | -85.98% | 🇮🇱 Israel |
 Cleveland BioLabs
CBLI | N/A | N/A | 🇺🇸 USA |
 Emergent BioSolutions
EBS | 0.0983 | -98.60% | 🇺🇸 USA |